Skip to content
Back to ADPT

Adaptive Biotechnologies Corp

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
185
Purchases
0
Sales
185
Purchase value
$0.00
Sale value
$127.34M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 11, 20260001780664-26-000055
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 13, 2026
Common StockF1F511,466$28.93$331.71K377,802Direct
SaleNov 12, 2026
Common StockF1F411,881$29.40$349.30K377,802Direct
SaleNov 11, 2026
Common StockF1F24,983$30.29$150.94K384,700Direct
SaleNov 11, 2026
Common StockF1F36,898$31.22$215.36K377,802Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.63, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.74 to $29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 to $29.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The option is fully vested and exercisable.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 11, 20260001820885-26-000027
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 11, 2026
Common StockF11,875$32.00$60.00K387,475Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Nov 10, 2026Period of report Nov 9, 20260001780664-26-000053
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF1F59,981$29.35$292.94K379,702Direct
SaleNov 10, 2026
Common StockF1F61,900$30.41$57.78K377,802Direct
SaleNov 9, 2026
Common StockF1F21,100$28.87$31.76K388,583Direct
SaleNov 9, 2026
Common StockF1F38,381$30.15$252.69K380,202Direct
SaleNov 9, 2026
Common StockF1F42,400$30.58$73.39K377,802Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.41 to $29.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Nov 6, 2026Period of report Nov 4, 20260001780664-26-000051
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 6, 2026
Common StockF1F78,400$27.32$229.49K381,283Direct
SaleNov 6, 2026
Common StockF1F83,481$27.88$97.05K377,802Direct
SaleNov 5, 2026
Common StockF1F45,926$26.10$154.67K383,757Direct
SaleNov 5, 2026
Common StockF1F55,455$26.88$146.63K378,302Direct
SaleNov 5, 2026
Common StockF1F6500$27.70$13.85K377,802Direct
SaleNov 4, 2026
Common StockF1F24,000$25.78$103.12K385,683Direct
SaleNov 4, 2026
Common StockF1F37,881$26.60$209.63K377,802Direct
Filing footnotes · 9
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  8. F8The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  9. F9The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Nov 3, 2026Period of report Oct 30, 20260001780664-26-000049
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 3, 2026
Common StockF1F611,881$25.98$308.67K377,802Direct
SaleNov 2, 2026
Common StockF1F49,296$25.23$234.54K380,387Direct
SaleNov 2, 2026
Common StockF1F52,585$26.34$68.09K377,802Direct
SaleOct 30, 2026
Common StockF1F29,486$26.55$251.85K380,197Direct
SaleOct 30, 2026
Common StockF1F32,395$27.45$65.74K377,802Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $27.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.21 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.88 to $25.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.65 to $26.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 29, 2026Period of report Oct 27, 20260001780664-26-000047
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 29, 2026
Common StockF1F611,881$28.27$335.88K377,802Direct
SaleOct 28, 2026
Common StockF1F411,681$28.44$332.21K378,002Direct
SaleOct 28, 2026
Common StockF1F5200$28.90$5.78K377,802Direct
SaleOct 27, 2026
Common StockF1F23,000$26.58$79.74K386,683Direct
SaleOct 27, 2026
Common StockF1F38,881$27.53$244.49K377,802Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 to $27.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.07 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $28.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 26, 2026Period of report Oct 22, 20260001780664-26-000045
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 26, 2026
Common StockF1F68,503$25.94$220.57K381,180Direct
SaleOct 26, 2026
Common StockF1F73,378$26.30$88.84K377,802Direct
SaleOct 23, 2026
Common StockF1F44,500$24.50$110.25K385,183Direct
SaleOct 23, 2026
Common StockF1F57,381$25.28$186.59K377,802Direct
SaleOct 22, 2026
Common StockF1F210,181$24.38$248.21K379,502Direct
SaleOct 22, 2026
Common StockF1F31,700$25.29$42.99K377,802Direct
Filing footnotes · 8
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.96 to $24.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.96 to $25.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.82 to $24.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $26.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.25 to $26.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  8. F8The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 21, 2026Period of report Oct 19, 20260001780664-26-000043
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 21, 2026
Common StockF1F45,999$25.25$151.47K383,684Direct
SaleOct 21, 2026
Common StockF1F55,882$25.57$150.40K377,802Direct
SaleOct 20, 2026
Common StockF1F311,781$24.53$288.99K377,902Direct
SaleOct 20, 2026
Common StockF1100$24.85$2.49K377,802Direct
SaleOct 19, 2026
Common StockF1F211,881$24.05$285.74K377,802Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.88 to $24.85, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.84 to $24.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.44 to $25.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.44 to $25.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 16, 2026Period of report Oct 14, 20260001780664-26-000041
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 16, 2026
Common StockF1F511,581$24.21$280.38K378,102Direct
SaleOct 16, 2026
Common StockF1F6300$25.45$7.64K377,802Direct
SaleOct 15, 2026
Common StockF1F411,881$25.61$304.27K377,802Direct
SaleOct 14, 2026
Common StockF1F26,781$25.57$173.39K382,902Direct
SaleOct 14, 2026
Common StockF1F35,100$25.82$131.68K377,802Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.70 to $25.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.70 to $26.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.19 to $25.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.98 to $24.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.29 to $25.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 13, 2026Period of report Oct 9, 20260001780664-26-000039
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 13, 2026
Common StockF1F511,881$25.50$302.97K377,802Direct
SaleOct 12, 2026
Common StockF1F39,181$25.35$232.74K380,502Direct
SaleOct 12, 2026
Common StockF1F42,700$26.07$70.39K377,802Direct
SaleOct 9, 2026
Common StockF1F211,881$26.41$313.78K377,802Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 8, 2026Period of report Oct 6, 20260001780664-26-000037
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 8, 2026
Common StockF1F711,881$25.66$304.87K377,802Direct
SaleOct 7, 2026
Common StockF1F611,881$26.40$313.66K377,802Direct
SaleOct 6, 2026
Common StockF1F29,381$27.36$256.66K380,302Direct
SaleOct 6, 2026
Common StockF1F31,100$28.21$31.03K379,202Direct
SaleOct 6, 2026
Common StockF1F4901$29.71$26.77K378,301Direct
SaleOct 6, 2026
Common StockF1F5499$30.53$15.23K377,802Direct
Filing footnotes · 8
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.89 to $27.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.89 to $28.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $30.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.34 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.95 to $26.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.23 to $26.09, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  8. F8The option is fully vested and exercisable.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Oct 8, 2026Period of report Oct 6, 20260001820885-26-000025
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 6, 2026
Common StockF16,444$30.00$193.32K389,350Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 1, 20260001780664-26-000035
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 5, 2026
Common StockF1F56,699$28.82$193.07K382,984Direct
SaleOct 5, 2026
Common StockF1F65,182$29.67$153.75K377,802Direct
SaleOct 2, 2026
Common StockF1F411,881$28.13$334.21K377,802Direct
SaleOct 1, 2026
Common StockF1F26,081$27.57$167.65K383,602Direct
SaleOct 1, 2026
Common StockF1F35,800$28.56$165.65K377,802Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $28.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The option is fully vested and exercisable.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 1, 20260001780660-26-000024
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common StockF1F28,094$27.52$222.75K239,565Direct
SaleOct 1, 2026
Common StockF1F318,698$28.61$534.95K220,867Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  6. F6The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Sep 18, 2026Period of report Sep 16, 20260001780660-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 16, 2026
Common StockF1F2107,537$28.02$3.01M228,736Direct
SaleSep 16, 2026
Common StockF1F37,869$28.57$224.82K220,867Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The option is fully vested and exercisable.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  6. F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  7. F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001820885-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common StockF11,195$27.00$32.27K395,794Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Katey Einterz OwenDirector
4
Filed Aug 28, 2026Period of report Aug 26, 20260001852578-26-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common Stock9,615$26.00$249.99K78,639Direct
Open on SEC EDGAR
Robert HershbergDirector
4
Filed Aug 20, 2026Period of report Aug 18, 20260001274139-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF115,000$24.39$365.85K62,347Direct
SaleAug 18, 2026
Common StockF215,664$24.41$382.36K46,683Direct
Filing footnotes · 3
  1. F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The option was fully vested and exercisable and would have expired on October 18, 2026.
Open on SEC EDGAR
Chad M RobinsDirector · CEO and Chairman
4
Filed Aug 19, 2026Period of report Aug 17, 20260001780649-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common StockF3278,472$24.48$6.82M2,180,722Direct
SaleAug 18, 2026
Common StockF4204$25.14$5.13K2,180,518Direct
SaleAug 17, 2026
Common StockF1318,799$25.08$8.00M2,183,043Direct
SaleAug 17, 2026
Common StockF22,525$25.57$64.56K2,180,518Direct
Filing footnotes · 5
  1. F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option was fully vested and exercisable and would have expired on February 7, 2028.
Open on SEC EDGAR
Peter M NeupertDirector
4
Filed Aug 19, 2026Period of report Aug 17, 20260001237566-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 17, 2026
Common StockF115,000$25.23$378.45K240,315Direct
SaleAug 17, 2026
Common StockF240,000$25.10$1.00M200,315Direct
SaleAug 17, 2026
Common StockF369,690$25.16$1.75M130,625Direct
Filing footnotes · 4
  1. F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The option was fully vested and exercisable and would have expired on October 18, 2026.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Aug 12, 2026Period of report Aug 10, 20260001820885-26-000020
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 10, 2026
Common StockF13,000$25.00$75.00K396,989Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Aug 3, 2026Period of report Jul 30, 20260001820885-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 30, 2026
Common StockF11,299$24.00$31.18K399,989Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Harlan S RobinsChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 23, 2026Period of report Jul 21, 20260001780851-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 21, 2026
Common StockF1F2278,698$21.72$6.05M1,025,760Direct
SaleJul 21, 2026
Common StockF1F3213,702$22.12$4.73M812,058Direct
Filing footnotes · 4
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The option was fully vested and exercisable.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Jul 20, 2026Period of report Jul 16, 20260001820885-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 16, 2026
Common StockF15,000$23.00$115.00K401,288Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jul 17, 2026Period of report Jul 15, 20260001780660-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Common StockF1F2105,762$22.59$2.39M230,713Direct
Filing footnotes · 4
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The option is fully vested and exercisable.
  4. F4The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Harlan S RobinsChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 7, 2026Period of report Jul 2, 20260001780851-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 2, 2026
Common StockF1F2239,351$21.74$5.20M1,166,547Direct
SaleJul 2, 2026
Common StockF1F3146,889$22.45$3.30M1,019,658Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 1, 20260001780660-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 2, 2026
Common StockF1F444,838$22.59$1.01M230,713Direct
SaleJul 1, 2026
Common StockF1F28,743$22.18$193.92K279,949Direct
SaleJul 1, 2026
Common StockF1F342,261$22.50$950.87K237,688Direct
Filing footnotes · 8
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option is fully vested and exercisable.
  6. F6The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  7. F7The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  8. F8The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Jul 6, 2026Period of report Jul 1, 20260001820885-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Common StockF1487$22.00$10.71K406,288Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Sharon BenzenoChief Commercial Ofc Imm Med
4Rule 10b5-1 plan disclosed
Filed Jun 30, 2026Period of report Jun 26, 20260001780854-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 29, 2026
Common StockF1F3154,768$21.14$3.27M221,278Direct
SaleJun 26, 2026
Common StockF1F211,034$21.00$231.71K272,751Direct
Filing footnotes · 7
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The option was fully vested and exercisable.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  6. F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  7. F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Jun 29, 2026Period of report Jun 25, 20260001820885-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 25, 2026
Common StockF15,000$20.50$102.50K406,775Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Michelle Renee GriffinDirector
4Rule 10b5-1 plan disclosed
Filed Jun 29, 2026Period of report Jun 25, 20260001229765-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 25, 2026
Common StockF1F252,084$20.18$1.05M15,625Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The option was fully vested and exercisable.
Open on SEC EDGAR
Harlan S RobinsChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 15, 20260001780851-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 16, 2026
Common StockF1F36,160$18.01$110.94K1,405,898Direct
SaleJun 15, 2026
Common StockF1F2100,000$17.37$1.74M1,412,058Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.14 to $17.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Jun 15, 2026Period of report Jun 11, 20260001820885-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 11, 2026
Common StockF15,000$19.00$95.00K411,775Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Susan BobulskyChief Commercial Officer, MRD
4Rule 10b5-1 plan disclosed
Filed Jun 8, 2026Period of report Jun 4, 20260001820885-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 4, 2026
Common StockF111,000$18.00$198.00K416,775Direct
Filing footnotes · 1
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Jun 8, 2026Period of report Jun 4, 20260001780660-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 4, 2026
Common StockF139,741$17.49$695.07K250,934Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The option is fully vested and exercisable.
  3. F3The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  4. F4The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Kyle PiskelChief Financial Officer
4
Filed May 20, 2026Period of report May 18, 20260001780662-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 18, 2026
Common StockF13,115$13.04$40.62K256,725Direct
Filing footnotes · 1
  1. F1This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 29, 2026Period of report Apr 27, 20260001780664-26-000032
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 27, 2026
Common StockF1F219,037$14.23$270.90K377,802Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 24, 2026Period of report Apr 22, 20260001780664-26-000030
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 24, 2026
Common StockF1F419,060$14.02$267.22K382,132Direct
SaleApr 23, 2026
Common StockF1F319,060$13.74$261.88K386,470Direct
SaleApr 22, 2026
Common StockF1F219,060$14.13$269.32K390,808Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $14.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $14.16, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 21, 2026Period of report Apr 17, 20260001780664-26-000028
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 21, 2026
Common StockF1F430,941$14.66$453.60K395,146Direct
SaleApr 20, 2026
Common StockF1F319,060$14.55$277.32K399,484Direct
SaleApr 17, 2026
Common StockF1F219,060$14.57$277.70K403,822Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.14 to $14.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $15.13, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  6. F6The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 16, 2026Period of report Apr 14, 20260001780664-26-000026
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 16, 2026
Common StockF1F419,060$14.18$270.27K408,160Direct
SaleApr 15, 2026
Common StockF1F319,060$14.61$278.47K412,498Direct
SaleApr 14, 2026
Common StockF1F219,060$14.56$277.51K416,836Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $14.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 13, 2026Period of report Apr 9, 20260001780664-26-000024
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 13, 2026
Common StockF1F615,722$12.95$203.60K424,512Direct
SaleApr 13, 2026
Common StockF1F73,338$14.08$47.00K421,174Direct
SaleApr 10, 2026
Common StockF1F418,660$12.75$237.92K425,912Direct
SaleApr 10, 2026
Common StockF1F5400$13.48$5.39K425,512Direct
SaleApr 9, 2026
Common StockF1F216,960$13.79$233.88K431,950Direct
SaleApr 9, 2026
Common StockF1F32,100$14.44$30.32K429,850Direct
Filing footnotes · 9
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  7. F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  8. F8The option is fully vested and exercisable.
  9. F9The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Harlan S RobinsChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Apr 10, 2026Period of report Apr 8, 20260001780851-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF1F210,000$14.85$148.50K1,512,058Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
  2. F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $14.65 to $15.06, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open on SEC EDGAR
Francis LOChief People Officer
4Rule 10b5-1 plan disclosed
Filed Apr 10, 2026Period of report Apr 8, 20260001780660-26-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF1F222,564$15.07$340.04K271,154Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 8, 2026Period of report Apr 6, 20260001780664-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF1F430,841$14.83$457.37K434,288Direct
SaleApr 8, 2026
Common StockF1100$15.48$1.55K434,188Direct
SaleApr 7, 2026
Common StockF1F319,060$13.56$258.45K438,526Direct
SaleApr 6, 2026
Common StockF1F219,060$14.33$273.13K442,864Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.39 to $13.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $15.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option is fully vested and exercisable.
Open on SEC EDGAR
Chad M RobinsDirector · CEO and Chairman
4Rule 10b5-1 plan disclosed
Filed Apr 8, 2026Period of report Apr 6, 20260001780649-26-000011
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common StockF1F337,263$15.19$566.02K2,180,518Direct
SaleApr 6, 2026
Common StockF1F283,332$14.41$1.20M2,217,781Direct
Filing footnotes · 3
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Apr 1, 20260001780664-26-000020
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 2, 2026
Common StockF1F319,060$14.60$278.28K447,202Direct
SaleApr 1, 2026
Common StockF1F219,060$14.45$275.42K451,540Direct
Filing footnotes · 4
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Mar 31, 2026Period of report Mar 27, 20260001780664-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 31, 2026
Common StockF1F519,060$13.45$256.36K455,878Direct
SaleMar 30, 2026
Common StockF1F419,060$12.63$240.73K460,216Direct
SaleMar 27, 2026
Common StockF1F22,738$12.49$34.20K480,876Direct
SaleMar 27, 2026
Common StockF1F316,322$13.48$220.02K464,554Direct
Filing footnotes · 6
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.10 to $13.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  6. F6The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Mar 26, 2026Period of report Mar 24, 20260001780664-26-000016
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 26, 2026
Common StockF1F419,060$14.12$269.13K468,892Direct
SaleMar 25, 2026
Common StockF1F319,060$14.27$271.99K473,230Direct
SaleMar 24, 2026
Common StockF1F219,060$13.70$261.12K477,568Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.82 to $14.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Mar 23, 2026Period of report Mar 19, 20260001780664-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 23, 2026
Common StockF1F419,060$13.83$263.60K481,906Direct
SaleMar 20, 2026
Common StockF1F319,060$13.37$254.83K486,244Direct
SaleMar 19, 2026
Common StockF1F219,060$13.18$251.21K490,582Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option is fully vested and exercisable.
Open on SEC EDGAR
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Mar 18, 2026Period of report Mar 16, 20260001780664-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 18, 2026
Common StockF1F419,060$13.18$251.21K494,920Direct
SaleMar 17, 2026
Common StockF1F319,060$13.40$255.40K499,258Direct
SaleMar 16, 2026
Common StockF1F219,060$13.41$255.59K503,596Direct
Filing footnotes · 5
  1. F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  4. F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  5. F5The option is fully vested and exercisable.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.